Case series:CAR-T

5 trials

Sponsors

The Affiliated Hospital of Xuzhou Medical University, the Affiliated Hospital of Xuzhou Medical University

Conditions

B cell malignanciesMultiple myelomaacute lymphoblastic leukemiaautoimmune diseasesplasmablastic lymphoma

Early Phase 1

A single-center, open-arm, single-arm clinical study for the safety and efficacy of CD19 CAR-T in the treatment of refractory autoimmune diseases

RecruitingChiCTR1900023139

The Affiliated Hospital of Xuzhou Medical Universityautoimmune diseases

Start: 2019-05-13Updated: 2019-05-20

Clinical study for anti-BCMA CAR-T in the treatment of refractory or recurrent plasmablastic lymphoma

RecruitingChiCTR1900025892

The Affiliated Hospital of Xuzhou Medical Universityplasmablastic lymphoma

Start: 2019-09-01Updated: 2019-09-16

An open, single-center, single-arm clinical study of t anti-BCMA CAR-T and anti-CD138 CAR-T therapy for relapsed and refractory multiple myeloma

Active, not recruitingChiCTR2000033194

the Affiliated Hospital of Xuzhou Medical UniversityMultiple myeloma

Start: 2020-05-25Updated: 2020-05-25

Phase 1

Clinical study of humanized CD19 CAR-T in the treatment of newly diagnosed adult acute lymphoblastic leukemia

RecruitingChiCTR1800017401

The Affiliated Hospital of Xuzhou Medical Universityacute lymphoblastic leukemia

Start: 2018-08-01Updated: 2018-07-31

Unknown Phase

Clinical study for anti-CD79b CAR-T in the treatment of refractory or recurrent CD79b+ B cell malignancies

RecruitingChiCTR1900025891

The Affiliated Hospital of Xuzhou Medical UniversityB cell malignancies

Start: 2019-09-01Updated: 2019-09-16